Goldman Sachs
CERO

Goldman Sachs’s CERo Therapeutics CERO Stock Holding History

Goldman Sachs’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-81
Closed -$9.75K – 6452
2024
Q4 		$9.75K Buy
+81
New +$18.9K ﹤0.01% 5931

Other funds holding CERO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
APP
Avantax Planning Partners Dubuque, Iowa $4.02B AUM 20% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Goldman Sachs's CERO Position: Q1 2025 in Review

Goldman Sachs sold out of CERo Therapeutics (CERO) in Q1 2025, closing a stake of 81 shares — an estimated $9.75K sold.

Goldman Sachs first reported a position in CERO in Q4 2024 and held it in 1 quarter. The position peaked at $9.75K in Q4 2024. 13 funds tracked by Wall St. Rank hold CERO as of Q1 2025.

  • Goldman Sachs reported no remaining CERo Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Goldman Sachs sold 81 CERo Therapeutics shares in Q1 2025, an estimated $9.75K.
  • Goldman Sachs first reported a position in CERo Therapeutics in Q4 2024 and held it in 1 quarter.
  • Goldman Sachs's CERo Therapeutics position peaked at $9.75K in Q4 2024.
  • 13 funds tracked by Wall St. Rank held CERo Therapeutics as of Q1 2025.

Based on Goldman Sachs's 13F filing for Q1 2025, filed 9 May 2025.